Yes, you can switch from pravastatin 40 mg to atorvastatin 80 mg on the same day if lipid-lowering is suboptimal.
When pravastatin 40 mg fails to achieve adequate LDL-C reduction, immediate same-day switching to atorvastatin 80 mg is appropriate and supported by both FDA labeling and clinical guidelines. No washout period is required between statins 1, 2.
Rationale for Same-Day Switching
Statin Intensity Classification
According to the 2018 AHA/ACC guidelines, pravastatin 40 mg is classified as moderate-intensity therapy (achieving 30-49% LDL-C reduction), while atorvastatin 80 mg is high-intensity therapy (achieving ≥50% LDL-C reduction) 3, 4. When moderate-intensity therapy proves inadequate, escalation to high-intensity therapy is the logical next step.
FDA-Approved Dosing Guidance
The pravastatin FDA label explicitly states: "For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment" 1. This directly supports switching to a more potent statin like atorvastatin when pravastatin is insufficient—even at the maximum 80 mg dose, let alone at 40 mg.
Atorvastatin can be initiated at any dose from 10-80 mg once daily, with or without food, and requires no special timing considerations 2.
Expected Clinical Benefit
Magnitude of LDL-C Reduction
The switch from pravastatin 40 mg to atorvastatin 80 mg provides substantial additional lipid-lowering:
- Pravastatin 40 mg achieves approximately 32% LDL-C reduction 5
- Atorvastatin 80 mg achieves approximately 51% LDL-C reduction 6
This represents an additional 19% reduction in LDL-C, which translates directly to cardiovascular risk reduction (approximately 1% ASCVD risk reduction per 1% LDL-C lowering) 4.
Evidence from Direct Comparison Trials
The PROVE IT-TIMI 22 trial directly compared pravastatin 40 mg versus atorvastatin 80 mg in acute coronary syndrome patients and demonstrated:
- Median LDL-C achieved: 95 mg/dL with pravastatin vs 62 mg/dL with atorvastatin (P <0.001)
- 16% relative risk reduction in major cardiovascular events with atorvastatin (P = 0.005)
- Benefit apparent as early as 30 days after switching 6
The REVERSAL trial showed that atorvastatin 80 mg halted atherosclerosis progression (−0.4% change in atheroma volume) while pravastatin 40 mg showed continued progression (+2.7%, P = 0.02) 7.
Practical Implementation
How to Switch
- Stop pravastatin 40 mg
- Start atorvastatin 80 mg the same day (no gap needed)
- Take once daily at any time, with or without food 2
- Reassess LDL-C in 4-12 weeks to confirm adequate response 4, 2
Safety Considerations
The safety profile of atorvastatin 80 mg is comparable to lower doses:
- No increased risk of adverse events compared to atorvastatin 40 mg in veteran populations 8
- Myalgia rates similar between doses (11% vs 7%, P = 0.33) 8
- Discontinuation rates not significantly different 8
Monitor for myopathy symptoms (unexplained muscle pain, tenderness, weakness), particularly if the patient has risk factors: age ≥65 years, renal impairment, hypothyroidism, or concomitant medications that increase statin levels 2.
Common Pitfalls to Avoid
- Don't wait weeks between stopping one statin and starting another—this leaves the patient unprotected
- Don't start with atorvastatin 40 mg as an intermediate step—if high-intensity therapy is needed, go directly to 80 mg
- Don't forget to recheck lipids—assess response at 4-12 weeks to ensure goal achievement 4
- Don't ignore drug interactions—review medications that may increase atorvastatin levels (e.g., clarithromycin, cyclosporine) 2
Goal Achievement Expectations
After switching to atorvastatin 80 mg, expect:
- 44% of patients to achieve dual goals of LDL-C <70 mg/dL and CRP <2 mg/L (compared to only 11% with pravastatin 40 mg) 9
- More patients reaching aggressive lipid targets, particularly in secondary prevention settings 9
The switch is both clinically effective and cost-effective, with superior outcomes justifying the therapeutic change 5, 10.